MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models

    FAZ. Dustov, SEO. Seo (Tashkent, Uzbekistan)

    Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…
  • 2024 International Congress

    Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.

    S. Jain (Gandhinagar, India)

    Objective: Although levodopa is the preferred medication for treating Parkinson's disease, it has a very poor brain absorption and limited oral bioavailability. The goal of…
  • 2024 International Congress

    Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study

    S. Aslam, M. Olson, S. Felson, F. Ponce, H. Shill (Aurora, USA)

    Objective: To assess the feasibility of an aerobic exercise regimen in those with advanced PD and DBS. Background: Aerobic exercise is known to have beneficial…
  • 2024 International Congress

    AAV-mediated gene therapy for GBA-PD

    S. Ayloo, J. Ryu, S. Chou, C. Miller, L. Blatnik, E. Wischhof, J. Bu, W. Mccarty, L. Guo, S. Nass, C. O'Riordan, B. Elmer, C. Mueller, S. Ramachandran (Waltham, USA)

    Objective: Development of a gene therapy-based drug for treatment of GBA-PD, a genetic subtype of Parkinson’s disease Background: Mutations in GBA1, the gene encoding glucocerebrosidase…
  • 2024 International Congress

    Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

    D. Kremens, F. Amjad, S. Thakkar, B. Naderi, D. Martins, J. Rocha, G. Banisadr, S. Fisher (Wynnewood, USA)

    Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

    AA. Vanderplas (Leiderdorp, Netherlands)

    Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease

    R. Hughes, O. Bandmann, L. Ferraiuolo, H. Mortiboys (Sheffield, United Kingdom)

    Objective: To undertake a repurposing drug screen for Parkinson’s disease (PD) and further investigate the mechanism of action of top hits. To assess, in vivo,…
  • 2024 International Congress

    Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease

    G. Agyeah, J. Ghelfi, L. Gallucci, A. Rakovic, P. Antony, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

    Objective: Explore metabolic modulation as a disease-modifying target for inflammation in PRKN-PD Background: The release of mitochondrial DNA (mtDNA) is a well-documented phenotype in PRKN-linked…
  • 2024 International Congress

    Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging

    E. Klinman, A. Yoo (St Louis, USA)

    Objective: To determine age-associated changes in the size, density, movement, and dynamics of mitochondria as a function of sex, using microRNA-induced neurons derived from primary…
  • 2024 International Congress

    Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease

    ST. Tsai, MK. Lu, CH. Tsai, Y. Aoh, ZL. Lai, YY. Hsu, DS. Chao, PR. Hsueh (Taichung, Taiwan)

    Objective: To compare the gut microbiota in patients with Parkinson’s disease (PD) and healthy controls and predict the functional pathways associated with these differences. Background:…
  • « Previous Page
  • 1
  • …
  • 150
  • 151
  • 152
  • 153
  • 154
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley